A new drug developed by the Russian company BIOCAD has shown efficacy in fighting skin, lung, bladder, kidney, head and neck cancer.
Oleg Salagaev, head of the Ministry of Health's Communications Department, quoted BIOCAD company president Dmitry Morozov when he explained that the new drug differs from traditional chemotherapeutic agents because it continues to work even after patients stop taking it.
According to Salagaev, the drug works by triggering an immune response which allows the body to fight the tumor. In this way, even patients with severe forms of cancer have a chance at survival.
On Dec. 28 Russian Minister of Health Veronika Skvortsova announced that a new anti-cancer drug is undergoing trials in Russia. The working name of the drug is PD-1, but it will receive a new name once it's approved for the market.
Earlier Pascal Sorio, an executive from the pharmaceutical company AstraZeneca, told the Kommersant newspaper that research is underway at Skolkovo to find and fund Russian projects in the field of oncology. The projects are mostly concerning diagnostic systems, including molecular cancer diagnosis.
A Message from The Moscow Times:
Dear readers,
We are facing unprecedented challenges. Russia's Prosecutor General's Office has designated The Moscow Times as an "undesirable" organization, criminalizing our work and putting our staff at risk of prosecution. This follows our earlier unjust labeling as a "foreign agent."
These actions are direct attempts to silence independent journalism in Russia. The authorities claim our work "discredits the decisions of the Russian leadership." We see things differently: we strive to provide accurate, unbiased reporting on Russia.
We, the journalists of The Moscow Times, refuse to be silenced. But to continue our work, we need your help.
Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just $2. It's quick to set up, and every contribution makes a significant impact.
By supporting The Moscow Times, you're defending open, independent journalism in the face of repression. Thank you for standing with us.
Remind me later.
